| Targeting nuclear factor-kappa B to overcome resistance to chemotherapy P Godwin, AM Baird, S Heavey, MP Barr, KJ O’byrne, K Gately Frontiers in oncology 3, 120, 2013 | 312 | 2013 |
| Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC S Heavey, KJ O’Byrne, K Gately Cancer treatment reviews 40 (3), 445-456, 2014 | 168 | 2014 |
| PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer S Luszczak, C Kumar, VK Sathyadevan, BS Simpson, KA Gately, ... Signal transduction and targeted therapy 5 (1), 7, 2020 | 71 | 2020 |
| VERDICT MRI for prostate cancer: intracellular volume fraction versus apparent diffusion coefficient EW Johnston, E Bonet-Carne, U Ferizi, B Yvernault, H Pye, D Patel, ... Radiology 291 (2), 391-397, 2019 | 66 | 2019 |
| INNOVATE: A prospective cohort study combining serum and urinary biomarkers with novel diffusion-weighted magnetic resonance imaging for the prediction and characterization of … E Johnston, H Pye, E Bonet-Carne, E Panagiotaki, D Patel, M Galazi, ... BMC cancer 16, 1-11, 2016 | 54 | 2016 |
| MicroRNA-17 is downregulated in esophageal adenocarcinoma cancer stem-like cells and promotes a radioresistant phenotype N Lynam-Lennon, S Heavey, G Sommerville, BAS Bibby, B Ffrench, ... Oncotarget 8 (7), 11400, 2017 | 44 | 2017 |
| Apparatus for histological validation of in vivo and ex vivo magnetic resonance imaging of the human prostate RM Bourne, C Bailey, EW Johnston, H Pye, S Heavey, H Whitaker, B Siow, ... Frontiers in oncology 7, 255782, 2017 | 36 | 2017 |
| The oncogene metadherin interacts with the known splicing proteins YTHDC1, Sam68 and T-STAR and plays a novel role in alternative mRNA splicing HJ Luxton, BS Simpson, IG Mills, NR Brindle, Z Ahmed, V Stavrinides, ... Cancers 11 (9), 1233, 2019 | 33 | 2019 |
| Strategic targeting of the PI3K–NFκB axis in cisplatin-resistant NSCLC S Heavey, P Godwin, AM Baird, MP Barr, K Umezawa, S Cuffe, SP Finn, ... Cancer biology & therapy 15 (10), 1367-1377, 2014 | 32 | 2014 |
| Targeting NF-κB-mediated inflammatory pathways in cisplatin-resistant NSCLC SL Ryan, S Beard, MP Barr, K Umezawa, S Heavey, P Godwin, SG Gray, ... Lung Cancer 135, 217-227, 2019 | 28 | 2019 |
| Current perspectives on targeting PIM kinases to overcome mechanisms of drug resistance and immune evasion in cancer T Malone, L Schäfer, N Simon, S Heavey, S Cuffe, S Finn, G Moore, ... Pharmacology & therapeutics 207, 107454, 2020 | 26 | 2020 |
| In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC S Heavey, S Cuffe, S Finn, V Young, R Ryan, S Nicholson, N Leonard, ... Oncotarget 7 (48), 79526, 2016 | 26 | 2016 |
| Cellular senescence as a possible link between prostate diseases of the ageing male G Fiard, V Stavrinides, ES Chambers, S Heavey, A Freeman, R Ball, ... Nature Reviews Urology 18 (10), 597-610, 2021 | 25 | 2021 |
| An optimised saliva collection method to produce high-yield, high-quality RNA for translational research R Sullivan, S Heavey, DG Graham, R Wellman, S Khan, S Thrumurthy, ... PloS one 15 (3), e0229791, 2020 | 24 | 2020 |
| VERDICT MRI validation in fresh and fixed prostate specimens using patient‐specific moulds for histological and MR alignment C Bailey, RM Bourne, B Siow, EW Johnston, M Brizmohun Appayya, ... NMR in Biomedicine 32 (5), e4073, 2019 | 24 | 2019 |
| Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer L Li, L Hobson, L Perry, B Clark, S Heavey, A Haider, A Sridhar, G Shaw, ... British journal of cancer 123 (6), 1024-1032, 2020 | 20 | 2020 |
| Histological analysis of fat grafting with platelet‐rich plasma for diabetic foot ulcers—A randomised controlled trial GS Nolan, OJ Smith, S Heavey, G Jell, A Mosahebi International Wound Journal 19 (2), 389-398, 2022 | 18 | 2022 |
| Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth E Scott, K Hodgson, B Calle, H Turner, K Cheung, A Bermudez, ... Oncogene 42 (12), 926-937, 2023 | 17 | 2023 |
| Evaluation of PSA and PSA density in a multiparametric magnetic resonance imaging-directed diagnostic pathway for suspected prostate cancer: the INNOVATE trial H Pye, S Singh, JM Norris, LM Carmona Echeverria, V Stavrinides, A Grey, ... Cancers 13 (8), 1985, 2021 | 14 | 2021 |
| Avoiding unnecessary biopsy after multiparametric prostate MRI with VERDICT analysis: The INNOVATE study S Singh, H Rogers, B Kanber, J Clemente, H Pye, EW Johnston, T Parry, ... Radiology 305 (3), 623-630, 2022 | 13 | 2022 |
Kathy GatelyTrinity College DublinVerified email at tcd.ie
